All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about treatment sequencing in myelofibrosis. The session was chaired by Jean-Jacques Kiladjian and involved an analysis from Claire Harrison, Haifa Kathrin Al-Ali, Tiziano Barbui, and John Mascarenhas.

Treatment sequencing in myelofibrosis

Key topics of discussion included: “When to start JAK inhibitors in patients with myelofibrosis (MF)”; “An analysis of key parameters that clinicians should look for in a hypothetical patient case”; “When to switch therapy”; and “The most promising drug classes that may change patient outcomes in the future, in particular, add-on strategies involving BET + JAK inhibitors and navitoclax”.